PCPs Report Status as Lockdown Lifts: Results from a National Primary Care Survey

Slideshow

Worry is mounting among PCPs about what’s coming after the initial COVID-19 pandemic wave, suggest results from week 8 of the Primary Care Collaborative’s Primary Care & COVID-19 Survey.

The Primary Care Collaborative released the Primary Care & COVID-19: Week 8 Survey results with 773 physicians who participated from 49 states between May 1, 2020 and May 4, 2020. The majority of respondents specialize in family medicine (70%), followed by internal medicine (11%), pediatrics (7%), and geriatrics (6%). What did the primary care physicians (PCPs) have to say about their COVID-19 experience? Find out in the slides below.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Related Content
FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years

FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years

Sydney Jennings
July 10th 2025
Article

Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Image courtesy of Cincinnati Children's

Intranasal COVID-19 Vaccine Found Safe and Immunogenic in Open Label Phase 1 Clinical Trial

Grace Halsey
July 7th 2025
Article

Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.

Cold & Flu Season 2022-23: AAFP Board Chair Shares Concerns

Cold & Flu Season 2022-23: AAFP Board Chair Shares Concerns

Sydney Jennings
October 25th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with American Academy of Family Physicians Board Chair Sterling Ransone, Jr, MD.

Kennedy's First Pass at US Vaccine Policy: ACIP Guidance Reversed, Clinical Trials Amended, WHO Abandoned / image credit ©Rafael Henrique/stock.adobe.com

Kennedy's First Pass at US Vaccine Policy: ACIP Guidance Reversed, Clinical Trials Amended, WHO Abandoned

Grace Halsey
June 2nd 2025
Article

Kennedy over 2 weeks has introduced changes in vaccination recommendations and research policy that undermine already tenuous public trust and understanding.

FDA Advisory Panel Recommends Continued Use of Monovalent JN.1 Strain for COVID-19 Vaccines / Image credit: ©Tada Images/AdobeStock

FDA Advisory Panel Recommends Continued Use of Monovalent JN.1 Strain for COVID-19 Vaccines

Sydney Jennings
May 27th 2025
Article

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

© 2025 MJH Life Sciences

All rights reserved.